Rituximab And Intestinal Perforation – A Rare Association

Inês Coelho Mogárrio; Filipa Bragança Jalles; Maria Knoblich; Mafalda de Castro; Rui Alves

doi:10.34635/rpc.1044

Inês Coelho Mogárrio Hospital Dr. Nélio Mendonça – Hospital Central do Funchal; Hospital Dona Estefânia – Unidade Local de Saúde de São José, Portugal http://orcid.org/0009-0007-1551-2681
Filipa Bragança Jalles Hospital Dona Estefânia – Unidade Local de Saúde de São José, Portugal
Maria Knoblich Hospital Dona Estefânia – Unidade Local de Saúde de São José, Portugal
Mafalda de Castro Hospital Dona Estefânia – Unidade Local de Saúde de São José, Portugal
Rui Alves Hospital Dona Estefânia – Unidade Local de Saúde de São José, Portugal

DOI: https://doi.org/10.34635/rpc.1044

Abstract

.

Downloads

Download data is not yet available.

References

1. Adashek M, Chan A, Medina A. Gastrointestinal Perforation after Rituximab Therapy in Mantle Cell Lymphoma: A Case Report. Case Rep Oncol. 2018 Sep-Dec; 11(3): 784–790. doi: 10.1159/000494828.
2. Sullivan BJ, Kim G, Sara G. Treatment dilemma for survivors of rituximab-induced bowel perforation in the setting of post-transplant lymphoproliferative disorder. BMJ Case Rep. 2018; 11(1): e226666. doi: 10.1136/bcr-2018-226666.
3. Ghrenassia E, Mariotte E, Azoulay E. Rituximab-related Severe Toxicity. Annual Update in Intensive Care and Emergency Medicine 2018. 2018 : 579–596. doi: 10.1007/978-3-319-73670-9_43.
4. Lowe CS, Rickinson AB, Bell A. Epstein–Barr virus-associated lymphomas. Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19; 372(1732): 20160271. doi: 10.1098/rstb.2016.0271.
5. Kutsch E, Kreiger P, Consolini D, Furuya KN. Colonic perforation after rituximab treatment for posttransplant lymphoproliferative disorder. J Pediatr Gastroenterol Nutr . 2013 Jun;56(6):e41. doi: 10.1097/MPG.0b013e3182519cfc.